Navigation Links
Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Date:12/13/2007

CAMBRIDGE, Mass., Dec. 13 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) announced today that its Late Onset Treatment Study (LOTS) of Myozyme(R) (alglucosidase alfa) met its co-primary efficacy endpoints. The study was undertaken to evaluate the safety and efficacy of Myozyme in juvenile and adult patients with Pompe disease. Myozyme was first approved in 2006, and the product is now registered in 36 countries.

The randomized, double-blind, placebo-controlled study enrolled 90 patients at eight primary sites in the United States and Europe. Participants received either Myozyme or a placebo every other week for 18 months. The average age of study participants was 44 years. The primary efficacy endpoints of the study sought to determine the effect of Myozyme on functional endurance as measured by the six-minute walk test and to determine the effect of Myozyme on pulmonary function as measured by percent predicted forced vital capacity.

The results showed that, at 18 months, patients treated with Myozyme increased their distance walked in six minutes by an average of approximately 30 meters as compared with the placebo group (P=0.0283; Wilcoxon test). The placebo group did not show any improvement from baseline. The average baseline distance walked in six minutes in both groups was approximately 325 meters.

Percent predicted forced vital capacity in the group of patients treated with Myozyme increased by 1 percent at 18 months. In contrast, it declined by approximately 3 percent in the placebo group (P=0.0026; Wilcoxon test). The average baseline percent predicted forced vital capacity in both groups was approximately 53 percent.

The results for both efficacy endpoints were consistent across various prosp
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Leatherwood Plastics has ... material, to stay competitive in the semiconductor, clean ... materials ultimately impact product quality and productivity, according ... , Established in 1980 in Lewisville, TX, ... fabricators have left the business. Much of Leatherwood’s ...
(Date:9/18/2014)... Sept. 18, 2014  Neogen Corporation (Nasdaq: ... a strategic agreement with Merck Animal Health to market ... The Igenity Dairy Heifer Program consists of genomic ... the genetic potential of replacement dairy heifers. The genomic ... born, and is an excellent tool in the decision-making ...
(Date:9/18/2014)... LOUIS , Sept. 18, 2014   ... announced today it has entered into a new ... (U-M) Medical School,s Vector Core. Under the partnership, ... CRISPR technology, experimental design consultation, and dedicated gene ... to accelerate gene editing-based research at the U-M ...
(Date:9/18/2014)... dysplasia is a group of rare diseases that ... cartilage. Its onset hits at the fetal stage ... in the gene encoding fibroblast growth factor receptor ... of skeletal dysplasia, thanatophoric dysplasia (TD), a skeletal ... and is often lethal, and achondroplasia (ACH), which ...
Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Merck Animal Health to market Neogen's dairy genomic program 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3
... U.S. ... business, BOSTON, MA ... Hand, the world,s first commercially,available bionic hand, today announced that it has ... the,United States., Bill Graham has been named U.S. sales manager for ...
... PLC Systems Inc.,(Amex: PLC ) today announced that ... Conference on February 18-21, 2008 at the Ritz,Carlton Laguna Niguel ... 20th beginning at 3:30 pm local time. Presenting for the ... webcast of the presentation will be available at the company,s,website ...
... Open DICOM Standard DR and Data Management Systems Spurs ... Forty-Five Percent Growth for Company, ... a,leading developer of digital radiography (DR), PACS (Picture Archiving and,Communications ... the company,s revenues grew 45 percent,to surpass $35 million for ...
Cached Biology Technology:Touch Bionics adds to sales, marketing, production and design teams 2Touch Bionics adds to sales, marketing, production and design teams 3PLC Systems to Present at the ROTH Conference 2Eklin Medical Reports Record Revenues for 2007 2Eklin Medical Reports Record Revenues for 2007 3
(Date:9/18/2014)... people are too stressed they are often grouchy, grumpy, ... Institute (BMI) at EPFL have just highlighted a fundamental ... and the loss of social skills and cognitive impairment. ... regulatory molecule in the brain. This was revealed by ... , Carmen Sandi,s team went to look for answers ...
(Date:9/17/2014)... reproductive technologies, the justice and well-being of our ... identify key issues, articulate their values and concerns, ... defensible ways forward. But what are the best ... Hastings Center and the Presidential Commission for the ... publish a series of essays to highlight the ...
(Date:9/17/2014)... A rare genetic disorder known as Jacobsen syndrome has ... investigation by researchers at San Diego State University and ... suggesting better treatment options for people with Jacobsen syndrome, ... underpinnings of autism., Jacobsen syndrome affects approximately 1 in ... It occurs in a person when there is a ...
Breaking Biology News(10 mins):How stress tears us apart 2Why bioethics literacy matters 2Why bioethics literacy matters 3A link between Jacobsen syndrome and autism 2
... Scientists across the world are building an extensive repository ... understanding the function of the approximately 57,000 genes that ... Rice Functional Genomics Consortium recently announced the public availability ... mutations in about half of the known functional genes ...
... people are affected with retinitis pigmentosa (RP), a disease ... blindness. Now, a University of Missouri researcher has identified ... different forms of RP. This discovery will help scientists ... humans. "The same genetic mutations ...
... WASHINGTON, DC As researchers continue to examine ... ,important that people understand the differences among various ... Corn Refiners Association (CRA). Interchanging two distinctly different ... corn syrup, creates factually incorrect conclusions and misleads ...
Cached Biology News:200,000 rice mutants available worldwide for scientific investigation 2Cats' eye diseases genetically linked to diseases in humans 2Pure fructose frequently confused with high fructose corn syrup 2